Aug 9, 2024 5:59 pm EDT Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Jul 24, 2024 6:00 am EDT Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
Jul 11, 2024 7:15 am EDT Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
Jun 10, 2024 7:00 am EDT Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
May 10, 2024 7:00 am EDT Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
Apr 30, 2024 7:00 am EDT Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting